The CEO of the Saidal Group, Mourad Belkhelfa, received the Chargé d’Affaires of the United States Embassy in Algeria, Mark A. Shapiro, along with a delegation from the American laboratory Abbott, on Tuesday at Saidal’s “Constantine 1” production site.
🤝 Joining Forces: #Saidal and US-based #Abbott express a shared vision to strengthen their strategic pharmaceutical cooperation! 🇩🇿🇺🇸💊
— Algeria Gate -English (@algatedzEng) May 13, 2026
The details here:https://t.co/pNr290BYpu pic.twitter.com/RbI2c45Q6g
According to a statement issued by the Saidal Group on Wednesday, discussions during the meeting focused on the “Influvac” flu vaccine as part of the ongoing partnership with Abbott. The US delegation expressed its deep appreciation for this strategic cooperation, praising the high quality of Saidal’s infrastructure and the efficiency of its workforce.
For his part, Belkhelfa provided an overview of the Saidal Group’s ambitious projects, including its cell therapy program, which reflects the group’s strong commitment to innovation and advanced medical research.
Both parties reaffirmed their shared desire to enhance cooperation between Saidal and Abbott, contributing to the development of Algeria’s pharmaceutical sector and ensuring the provision of innovative health solutions for its citizens.


